Clinical Trials in Russia. 1st Quarter 2011.

Moscow, Russia, June 08, 2011 --(PR.com)-- Synergy Research Group (SynRG), a Russia-based CRO, presented the English version of SynRG Orange Paper Q3 2010, the quarterly analytical report on the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects of the Russian clinical trial market. This is another step to formation of a civilized market of clinical trials in Russia and improvement of the research attractiveness of Russia for foreign sponsors, one of the SynRG’s key strategic goals.

The Ministry of Health and Social Development of the Russian Federation (alias MoH) approved 95 new clinical trials of all types including local studies during the first quarter of 2011, 29% less than in Q1 2010. The main contribution into the total number of studies is made by multinational multi-center clinical trials, the number of them also decreased by 11% from Q1 2010 and stood at 74 new studies in Q1 2011. The number of the local clinical trials conducted in Russia by domestic and foreign sponsors is also down from 36 to 18 clinical trials, two times less than in the same period in 2010.

Clinical trials in Russia in Q1 2011 were sponsored by companies from 15 countries. The maximum number of trials (22) were initiated by US sponsors; Russian sponsors with 19 studies took the runner-up place; they are followed by Swiss sponsors with 15 trials; ten new studies were instigated by the UK manufacturers. The top six is concluded by German and French sponsors each having six new studies in Q1 2011.

The number of subjects which are planned to be enrolled in the Phase II-IV trials launched in the first quarter of 2011 stood at 11,123 subjects, 15% less than in Q1 2010.

The GlaxoSmithKline sponsoring eight new studies is on the top of the heap in the first quarter of 2011. Novartis with six new trials in Q1 2011 took the runner-up place. It is followed by AstraZeneca sponsoring five new studies, and Roche also with five new studies, but with a smaller number of subjects. The top five is concluded by sanofi-aventis having four new studies in Q1 2011.

The Russian pharmaceutical company Materia Medica sponsoring four new clinical trials ranked number one among domestic pharmaceutical manufacturers by the number of new studies in the first quarter 2011. Petrovaks with two new trials took the runner-up place. It is followed by Veropharm, Vector-Medica and Sintez with one new study each differing only in the number of subjects and sites.

Seventy four percent of the new studies in Q1 2011 were conducted in the five leading therapeutic areas. The maximum number of trials (29) were initiated in Oncology; 12 clinical trials in Respiratory diseases; 11 new studies in Endocrinology; seven new studies in Cardiovascular diseases, and six new studies in Musculoskeletal diseases were initiated in Q1 2011.

Synergy Research Group (SynRG™) is a Russian contract research organization, which has been successfully operating in Russia since 2002. SynRG™ offers a broad range of services for conducting clinical trials for Russian and foreign pharmaceutical and biotechnological companies – from registration of the studies in regulatory authorities to pharmaco-economic surveys. The company has its own clinical depot in Moscow. Today, Synergy Research Group is represented in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg, Perm, Krasnodar, Rostov-on-Don, and also in Almaty and Astana (Kazakhstan) and Kyiv (Ukraine). The company’s headquarters are in Moscow.

###